top of page

Our latest thinking, insights and company news

CONTACT US TODAY

Never miss an update, subscribe today.

RJW&partners will only use your personal information to administer your account and provide the products and services you request. You can unsubscribe at any time, to do so please review our Privacy Policy. By clicking subscribe, you consent to allow RJW&partners to store and process your personal information.

Is it business as usual for Pharma in Russia?

Mar 23, 2022
2 min

Is it business as usual for Pharma in Russia?

A summary of the impact of Russia invasion of Ukraine on the biopharmaceutical industry so far

175 views

Mar 22, 2022
14 min

Rare diseases are not that rare after all...

What are the key drivers of willingness to pay for Orphan Medical Products (OMPs) in the UK, France, Germany, Italy & Spain?

55 views

Helen Johnson joins RJW&partners as Director

Jan 6, 2022
2 min

Helen Johnson joins RJW&partners as Director

We are delighted to announce the appointment of Helen Johnson as Director.

293 views

What have NICE and NHS England been up to in 2021?

Dec 17, 2021
10 min

What have NICE and NHS England been up to in 2021?

A summary of some of the key changes and announcements made by NICE and NHS England and NHS Improvement during 2021

172 views

How copay accumulators and maximizers are shifting drug costs to patients and manufacturers

Sep 7, 2021
5 min

How copay accumulators and maximizers are shifting drug costs to patients and manufacturers

Recently, healthcare insurance companies and PBMs have been leveraging two new strategies that shift further costs onto commercially-covered

4,328 views

The management of orphan drug prices after loss of exclusivity

Jun 29, 2021
4 min

The management of orphan drug prices after loss of exclusivity

What happens to orphan drugs when they lose market exclusivity? Do they face generic competition and price reductions like other drugs?...

870 views

bottom of page